MXCT vs BCYC

For growth investors, Bicycle Therapeutics plc (BCYC) is the stronger pick with 105.

8% revenue growth year-over-year, versus -14. 5% for MaxCyte, Inc. (MXCT). Analysts rate Bicycle Therapeutics plc (BCYC) a "Buy" — based on 21 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Bicycle Therapeutics plc (BCYC) delivered a total return of -84.

6%, compared to -94. 9% for MaxCyte, Inc. (MXCT). Over 10 years, the gap is even starker: BCYC returned -59. 3% versus MXCT's -94. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), MaxCyte, Inc.

(MXCT) is the lower-risk stock at 1. 44β versus Bicycle Therapeutics plc's 1. 65β — meaning BCYC is approximately 15% more volatile than MXCT relative to the S&P 500. On balance sheet safety, Bicycle Therapeutics plc (BCYC) carries a lower debt/equity ratio of 3% versus 10% for MaxCyte, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Bicycle Therapeutics plc (BCYC) is pulling ahead at 105.

8% versus -14. 5% for MaxCyte, Inc. (MXCT). On earnings-per-share growth, the picture is similar: MaxCyte, Inc. grew EPS -7. 7% year-over-year, compared to -9. 0% for Bicycle Therapeutics plc. Over a 3-year CAGR, BCYC leads at 71. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

MaxCyte, Inc.

(MXCT) is the more profitable company, earning -135. 1% net margin versus -301. 7% for Bicycle Therapeutics plc — meaning it keeps -135. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MXCT leads at -138. 3% versus -341. 3% for BCYC. At the gross margin level — before operating expenses — BCYC leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, MaxCyte, Inc.

(MXCT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Bicycle Therapeutics plc (BCYC) carries a higher beta of 1. 65 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MXCT: -94. 9%, BCYC: -59. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: MXCT is a small-cap quality compounder stock; BCYC is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.